Small protein plays big role in asthma severity

August 1, 2013, Federation of American Societies for Experimental Biology

A new culprit has been identified that likely plays a big role in the severity of asthma—a small protein chemokine called CCL26. These findings were published in the Journal of Leukocyte Biology and represent the first demonstration that CCL26 is a potent regulator of the migration of asthmatic eosinophils, commonly observed in asthmatic airways. Results from this discovery may lead to new drug targets for the treatment of asthma.

"We hope that these studies will help to develop a new treatment that would specifically abrogate bronchial inflammation and provide a specific, efficacious and well-tolerated alternative to the current therapy," said Michel Laviolette, M.D., a researcher involved in the work from the Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Québec, Faculté de Médecine, Université Laval, Québec, Canada.

Specifically, data from the report suggest that the chemokine CCL26 plays a crucial role in asthma and its severity by supporting the recruitment of eosinophils early in the development of the disease, and possibly later in severe asthma associated with persisting lung eosinophilia. To make this discovery, scientists used blood from healthy and asthmatic subjects to isolate eosinophils and measure their migration response to CCL26 in vitro. Researchers also assessed their response to other chemokines, CCL11 and CCL24, and showed that only CCL26 induced an amplified eosinophil migration of asthmatic eosinophils compared to healthy cells. Interestingly, this additional migration occurred after a 6-hour and, in contrast to the migration induced by the other chemokines, was not eradicated by blocking the chemokine receptor CCR3 shared by these three chemokines.

"The control of eosinophils is central to asthmatic diseases and the underlying mechanisms are prime targets for treatments for the debilitating and sometimes life-threatening symptoms of asthma and allergy," said John Wherry, Ph.D., Deputy Editor of the Journal of Leukocyte Biology. "This report shows that CCL26 could be a novel drug target to regulate in these diseases."

Explore further: A large subgroup of mild-to-moderate asthma is persistently non-eosinophilic

More information: Véronique Provost, Marie-Chantal Larose, Anick Langlois, Marek Rola-Pleszczynski, Nicolas Flamand, and Michel Laviolette. CCL26/eotaxin-3 is more effective to induce the migration of eosinophils of asthmatics than CCL11/eotaxin-1 and CCL24/eotaxin-2 . J Leukoc Biol August 2013 94:213-222; doi:10.1189/jlb.0212074

Related Stories

A large subgroup of mild-to-moderate asthma is persistently non-eosinophilic

January 6, 2012
A large percentage of patients with mild-to-moderate asthma have persistently non-eosinophilic disease which may not respond to currently available anti-inflammatory treatments, according to a new study.

Have asthma? You likely have an allergy as well

April 2, 2013
Asthma is becoming an epidemic in the United States. The number of Americans diagnosed with asthma grows annually, with 26 million currently affected. And according to a new study, nearly two-thirds or more of all asthmatics ...

Trial asthma drug targets lung inflammation

May 1, 2013
University of Adelaide researchers at the Royal Adelaide Hospital are involved in the world's biggest study of its kind investigating a possible new treatment for asthma.

A promising target to treat asthma

July 24, 2013
An enzyme known for its role in heart disease may well be a promising target to treat asthma. Researchers from the University of Iowa have found that the enzyme, called CaMKII, is linked to the harmful effects of oxidation ...

Recommended for you

Chronic inflammation causes loss of muscle mass during aging

January 12, 2018
People start losing muscle mass at the age of 40—about some 10 percent of the total muscle mass for each 10-year period, which may lead to fall-related injuries, slowing metabolism and reduced quality of life. Today, very ...

Breathing exercises help asthma patients with quality of life

December 13, 2017
A study led by the University of Southampton has found that people who continue to get problems from their asthma, despite receiving standard treatment, experience an improved quality of life when they are taught breathing ...

Study highlights the need for research into prevention of inflammatory bowel disease

December 7, 2017
Countries in Africa, Asia, the Middle East and South America have seen a rise in incidence of inflammatory bowel disease as they have become increasingly industrialised and westernised, a new study has found.

Air pollution can increase asthma risk in adults, even at low levels

November 24, 2017
Living close to a busy road can be bad for your respiratory health if you are middle aged, new Australian research has found.

Evidence found of oral bacteria contributing to bowel disorders

October 20, 2017
(Medical Xpress)—An international team of researchers has found evidence that suggests certain types of oral bacteria may cause or exacerbate bowel disorders. In their paper published in the journal Science, the group describes ...

New compound discovered in fight against inflammatory disease

September 22, 2017
A 10-year study by University of Manchester scientists for a new chemical compound that is able to block a key component in inflammatory illness has ended in success.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.